Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05118490
PHASE4

Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients

Sponsor: The Aurum Institute NPC

View on ClinicalTrials.gov

Summary

A multicenter, randomized, stratified, open-label, phase IV trial among HIV-positive persons (PLHIV) on antiretroviral therapy (ART), or HIV-negative household contacts of patients with rifampicin-sensitive pulmonary tuberculosis (TB), who do not have evidence of active TB.

Official title: A Randomized Trial Comparing Treatment Completion of Daily Rifapentine & Isoniazid for One Month (1HP) To Weekly Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in HIV-negative Household Contacts of Recently Diagnosed Tuberculosis Patients, The "One To Three" Trial

Key Details

Gender

All

Age Range

13 Years - Any

Study Type

INTERVENTIONAL

Enrollment

1000

Start Date

2023-07-19

Completion Date

2025-12-31

Last Updated

2025-12-12

Healthy Volunteers

No

Interventions

DRUG

Daily rifapentine and isoniazid for 4 weeks

Arm A: isoniazid (300mg) and rifapentine (600mg) daily for 4 weeks (1HP)

DRUG

Weekly rifapentine and isoniazid for 12 weeks

Arm B: isoniazid (900mg) and rifapentine (900mg) weekly for 12 weeks (3HP)

Locations (4)

The Byramjee Jeejeebhoy Medical Centre (BJGMC-JHU) CRS

Pune, Maharashtra, India

Yayasan KNCV - The Persahabatan Hospital, Jakarta

Jakarta, Jaya, Indonesia

Fundação Aurum (The Aurum Institute Mozambique)

Chokwé, Gaza Province, Mozambique

The Aurum Institute: Gavin J Churchyard Legacy Centre

Klerksdorp, North West, South Africa